Feature Channels: Clinical Trials

Filters close
3-Nov-2022 7:30 PM EDT
Shorter Course of Radiation Therapy Yields Comparable Results for Patients with Non-Metastatic Soft Tissue Sarcoma
University of Texas MD Anderson Cancer Center

Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor control and no increased risk of major complications in wound healing, according to researchers at The University of Texas MD Anderson Cancer Center.

Released: 4-Nov-2022 4:00 PM EDT
When Used as a Biomarker, MicroRNA Can Help Predict Which Breast Cancer Patients Are More Likely to See Their Cancer Come Back
American College of Surgeons (ACS)

MicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to study results published online ahead of print in the Journal of the American College of Surgeons (JACS).

2-Nov-2022 9:45 AM EDT
High-Impact Clinical Trials Yield Results that Could Improve Kidney Care
American Society of Nephrology (ASN)

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person and online at ASN Kidney Week 2022 November 3–November 6.

Released: 4-Nov-2022 10:20 AM EDT
A Major Clinical Trial Shows How to Reduce the Risk of Stomach Bleeding Occasionally Caused by Regular Aspirin Use
University of Nottingham

A new study, led by experts at the University of Nottingham found that the risk of stomach bleeding caused by using aspirin long-term, can be reduced with a short course of antibiotics, potentially improving the safety of aspirin when used to prevent heart attacks, strokes and possibly some cancers.

Released: 3-Nov-2022 3:50 PM EDT
Largest Trial to Date Shows That COMP360 Psilocybin Reduces Depression Symptoms
King's College London

A multicentre clinical trial led by COMPASS Pathways across 22 international sites including Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London and South London and Maudsley NHS Foundation Trust has found that a single 25mg dose of COMP360 psilocybin, alongside psychological support, had a significant impact in reducing symptoms of depression in participants with treatment-resistant depression.

   
Released: 3-Nov-2022 11:00 AM EDT
MD Anderson Research Highlights for November 3, 2022
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

   
Newswise: Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
Released: 2-Nov-2022 7:25 PM EDT
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
Roswell Park Comprehensive Cancer Center

A targeted therapy for children with high-risk Hodgkin lymphoma significantly reduced relapse rates, a large multicenter clinical trial conducted by the Children’s Oncology Group shows. The study results have been reported in the New England Journal of Medicine.

Newswise: Developing Therapies for Treatment-Resistant Prostate Cancer
Released: 2-Nov-2022 5:55 PM EDT
Developing Therapies for Treatment-Resistant Prostate Cancer
Cedars-Sinai

Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway.

31-Oct-2022 7:05 AM EDT
Dapagliflozin Is Not Only Clinically Effective, but Also Cost Effective in Patients with Chronic Kidney Disease
American Society of Nephrology (ASN)

A recent analysis indicates that dapagliflozin is a cost-effective treatment in patients with chronic kidney disease in addition to standard of care.

Released: 2-Nov-2022 1:20 PM EDT
Many Middle-Aged Adults Wary of Taking Part in Studies of Dementia Prevention Drugs
Michigan Medicine - University of Michigan

Drug companies and university-based teams are working urgently to find and test new medications that could prevent or slow the decline of brain function in older adults. But a new study suggests they’ll need to work harder to find volunteers for their clinical trials.

Released: 2-Nov-2022 11:30 AM EDT
American College of Rheumatology Educating Dermatologists and Nephrologists on Lupus Clinical Trials Racial Disparities
American College of Rheumatology (ACR)

The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their treatment areas and the importance of getting more of African American/Black patients enrolled.

Released: 2-Nov-2022 8:05 AM EDT
Ahead Study Is First to Test Lecanemab to Delay or Prevent Alzheimer's Disease Symptoms at the Stage of Preclinical AD
Alzheimer's Clinical Trials Consortium

The Alzheimer's Clinical Trial Consortium (ACTC) will be presenting analyses of screening plasma and neuroimaging data from the AHEAD Study at CTAD in November.

Newswise: Four Prospective, Multicenter Studies Support Use of Drug-Coated Balloons Over Bare Metal Stents in Treating Femoropopliteal Lesions
Released: 1-Nov-2022 2:15 PM EDT
Four Prospective, Multicenter Studies Support Use of Drug-Coated Balloons Over Bare Metal Stents in Treating Femoropopliteal Lesions
University Hospitals Cleveland Medical Center

New research published in the Journal of the American College of Cardiology shows the use of drug-coated balloons is an optimal approach compared to bare metal stents in treating femoropopliteal lesions.

Released: 1-Nov-2022 1:45 PM EDT
Monoclonal Antibody Prevents Malaria Infection in African Adults
NIH, National Institute of Allergy and Infectious Diseases (NIAID)

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.

Released: 1-Nov-2022 8:05 AM EDT
Can Butyrate Help Hispanic Children With Ulcerative Colitis?
Children's Hospital Los Angeles

New study is the first of its kind to focus on Hispanic children, who often have more severe disease. A novel clinical trial at Children’s Hospital Los Angeles is investigating whether butyrate—a short-chain fatty acid typically produced by gut bacteria—can be a potential therapy for children with ulcerative colitis.

25-Oct-2022 2:05 PM EDT
Ticagrelor–aspirin antiplatelet therapy more beneficial in persons with normal renal function
American College of Physicians (ACP)

An analysis of the CHANCE-2 trial has found that persons with normal renal function receive greater benefit from antiplatelet therapy with ticagrelor–aspirin versus clopidogrel–aspirin. The analysis is published in Annals of Internal Medicine.

Released: 31-Oct-2022 1:15 PM EDT
Breast Cancer Research Foundation Renews Support for Mount Sinai Research on Triple-Negative Breast Cancer
Mount Sinai Health System

The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer. The latest installment of $225,000 brings the total to almost $2 million over the past nine years. It will fund research into the immune microenvironment of triple-negative breast cancer in order to identify new strategies to enhance cancer-fighting immune responses for this aggressive breast cancer, which traditionally has few options for treatment.

Newswise: Breast Cancer Drug Benefits Broader Group of Patients, Trial Shows
Released: 31-Oct-2022 9:05 AM EDT
Breast Cancer Drug Benefits Broader Group of Patients, Trial Shows
UT Southwestern Medical Center

A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.

Released: 31-Oct-2022 8:05 AM EDT
How Do You Measure Success in Autism Clinical Trials?
Children's Hospital Los Angeles

Shafali Spurling Jeste, MD, shares early findings—and a critical challenge—from the Autism Biomarkers Consortium for Clinical Trials. How do you know if a treatment for autism is effective? That’s a question that has no easy answer—due in large part to the heterogeneous nature of autism spectrum disorder.

Newswise: Cedars-Sinai Awarded $8 Million to Launch New Stem Cell Clinic
Released: 28-Oct-2022 7:20 PM EDT
Cedars-Sinai Awarded $8 Million to Launch New Stem Cell Clinic
Cedars-Sinai

Cedars-Sinai has been awarded a five-year, $8 million grant from California’s stem cell agency to launch an innovative new clinic that will expand patients’ access to stem cell and gene therapies, increase research and training in regenerative medicine, foster greater collaboration with eight similar clinics across the state and help educate the public about stem cell and related therapies.

Newswise: Cancer Therapy Shows Potential to Treat Severe COVID-19 in Pre-Clinical Trials
Released: 27-Oct-2022 7:45 PM EDT
Cancer Therapy Shows Potential to Treat Severe COVID-19 in Pre-Clinical Trials
Sao Paulo Research Foundation (FAPESP)

An article published in Science Advances suggests that a type of cancer treatment known as immune checkpoint blockade may be beneficial in certain cases of severe COVID-19.

Released: 27-Oct-2022 6:00 PM EDT
Children with Resistant Leukemia Given CRISPR-Edited T Cells: Phase 1 Study Results Reported
University College London

Researchers at Great Ormond Street Hospital for Children (GOSH) and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) have used CRISPR/Cas9 technology to engineer donor T cells to try to treat seriously ill children with resistant leukemia, who had otherwise exhausted all available therapies.

Newswise: UC San Diego Joins National Trial to Test Drug for Treating MPOX
Released: 27-Oct-2022 12:00 PM EDT
UC San Diego Joins National Trial to Test Drug for Treating MPOX
University of California San Diego

UC San Diego will be one of multiple sites assessing the safety and efficacy of tecovirimat as a potential treatment for human monkeypox. Marketed as TPOXX, tecovirimat is an antiviral currently approved for treatment of human smallpox in adults and children caused by the variola virus.

Newswise:Video Embedded kidney-week-2022-the-world-s-premier-kidney-meeting-to-connect-people-from-across-the-globe
VIDEO
Released: 27-Oct-2022 8:05 AM EDT
Kidney Week 2022—the World’s Premier Kidney Meeting—to Connect People From Across the Globe
American Society of Nephrology (ASN)

The American Society of Nephrology (ASN) will hold Kidney Week, the world’s premier kidney meeting, in Orlando, FL, November 3–6, 2022. The results of scientific studies and high-impact clinical trials that will advance kidney-related research and medical care will be presented in-person and online.

Released: 26-Oct-2022 5:50 PM EDT
6 Mayo Clinic Staff Selected for Diversity in Clinical Trials Career Development Award
Mayo Clinic

Six Mayo Clinic staff are award recipients in Cohort II of the Robert A. Winn Diversity in Clinical Trials Career Development Award. The two-year program aims to train, develop and mentor diverse and community-oriented researchers and physicians to help increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations.

Released: 26-Oct-2022 2:45 PM EDT
Cancer Research Institute to Host Annual Virtual Immunotherapy Patient Summit on November 11-12, 2022
Cancer Research Institute

Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.

Released: 25-Oct-2022 3:10 PM EDT
New Drug Is Found Effective for Treating Complicated Urinary Tract Infections
Rutgers University-New Brunswick

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.

24-Oct-2022 10:05 AM EDT
Metastasis-Directed Radiation Therapy Plus Hormone Therapy Improves Progression-Free Survival for Men with Advanced Prostate Cancer
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Newswise: Targeting One Type of Immune Cell with Another Slows Cancer Growth in Preclinical Studies
Released: 25-Oct-2022 8:30 AM EDT
Targeting One Type of Immune Cell with Another Slows Cancer Growth in Preclinical Studies
Mount Sinai Health System

A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly attacking the cancer—provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York. The findings were published October 11, 2022 in the journal Cancer Immunology Research [https://doi.org/10.1158/2326-6066.CIR-21-1075]. The study involved a twist on a type of therapy that uses immune cells known as CAR T cells. CAR T cells in current clinical use are engineered to recognize cancer cells directly and have successfully treated several blood cancers. But there have been challenges that prevent their effective use in many solid tumors.

Released: 24-Oct-2022 3:55 PM EDT
Phase II clinical trial generates promising results for immunotherapy drug nivolumab in patients with advanced skin cancer
Wiley

Numerous studies have shown that drugs called immune checkpoint inhibitors can boost the immune system’s response against various cancers.

Released: 24-Oct-2022 2:55 PM EDT
University Hospitals Seidman Cancer Center Researchers Slash Time Needed to Produce CAR T-Cells
University Hospitals Cleveland Medical Center

Researchers at University Hospitals (UH) Seidman Cancer Center in Cleveland, Ohio and a biotech start-up company have developed a streamlined way to manufacture CAR T-cells for immunotherapy treatment in just 24 hours – an improvement over the team’s previous benchmark of eight days and commercial suppliers that typically take three weeks. The team is one of the first in the country to test this manufacturing approach.

21-Oct-2022 7:05 AM EDT
Three-Week Course of Radiation Safe and Effective for Patients with Early-Stage Breast Cancer and Elevated Risk of Recurrence
American Society for Radiation Oncology (ASTRO)

A three-week course of radiation therapy is as safe and effective as four to six weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a randomized phase III clinical trial show. Delivering fewer, but higher, doses of radiation following lumpectomy, while concurrently delivering a radiation boost to the surgical site, led to similar outcomes as a longer course of treatment.

21-Oct-2022 7:05 AM EDT
Lower Prostate Cancer Screening Rates Associated with Subsequent Increase in Advanced Cancers
American Society for Radiation Oncology (ASTRO)

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

21-Oct-2022 7:05 AM EDT
Adding Radiation to Systemic Therapy Extends Overall Survival for Patients with Advanced Liver Cancer
American Society for Radiation Oncology (ASTRO)

Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients’ quality of life, a randomized phase III clinical trial shows.

Newswise: Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
Released: 23-Oct-2022 12:05 PM EDT
Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
University of Texas MD Anderson Cancer Center

Using a novel response-adapted ultra-low dose radiation therapy strategy, MD Anderson researchers observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. The results were presented today at the 2022 ASTRO Annual Meeting.

21-Oct-2022 7:05 AM EDT
Radiation Therapy for High-Risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life
American Society for Radiation Oncology (ASTRO)

Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial (NCT03523351) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

21-Oct-2022 7:05 AM EDT
Medical Physicist Consults with Patients Can Help Reduce Anxiety and Increase Satisfaction with Radiation Care
American Society for Radiation Oncology (ASTRO)

Meeting with a medical physicist who can explain how radiation therapy is planned and delivered reduces patient anxiety and increases patient satisfaction throughout the treatment process, according to a new study published today in the International Journal of Radiation Oncology • Biology • Physics. Findings of the randomized, prospective phase III clinical trial also will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

21-Oct-2022 7:05 AM EDT
Shortened Course of Radiation Therapy Safe and Effective for Men with High-Risk Prostate Cancer
American Society for Radiation Oncology (ASTRO)

A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.

Released: 21-Oct-2022 4:45 PM EDT
New Analysis Led by UCLA Jonsson Comprehensive Cancer Center Finds Timing Androgen-Deprivation Therapy with Radiation Therapy Improves Outcomes in Localized Prostate Cancer
University of California, Los Angeles (UCLA), Health Sciences

In a large analysis of over 7,000 men treated internationally across 12 randomized trials, study shows that it is almost universally optimal for men to begin androgen deprivation therapy when starting radiation.

Released: 21-Oct-2022 1:50 PM EDT
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19
JAMA - Journal of the American Medical Association

Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery in this trial that enrolled more than 1,500 participants in the United States.

Released: 21-Oct-2022 1:10 PM EDT
Single Stranded Suture Threads Could Prevent Pregnancy Infection Complications, C-Stich Trial Finds
University of Birmingham

Women at risk of pregnancy loss who need a specialist surgical procedure could benefit from a single-stranded suture thread to reduce risk of infection, results from the C-STICH clinical trial found.

Released: 20-Oct-2022 2:05 PM EDT
GW School of Medicine and Health Sciences and the GW MFA Recruiting Participants for Final Stage of the NIAID’s COVAIL Trial
George Washington University

The GW School of Medicine and Health Sciences is recruiting participants for the final stage of a clinical trial to evaluate two Omicron-specific vaccines. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The George Washington University School of Medicine and Health Sciences has received funding support as an agreement under NIH contract number 75N91019D00024 to Leidos Biomedical Research in Frederick, Maryland.

Newswise: Study finds caregiver-child relationships improved after seven-session intervention
Released: 19-Oct-2022 2:30 PM EDT
Study finds caregiver-child relationships improved after seven-session intervention
UC Davis Health (Defunct)

A new study by researchers at UC Davis Children’s Hospital uses the first randomized controlled trial to evaluate PC-CARE’s effectiveness for children with challenging behaviors and their parents or caregivers. The study’s findings were recently published in the Journal of Child Psychiatry Human Development.

Released: 19-Oct-2022 2:05 PM EDT
New Clinical Trial Will Test Remote Monitoring to Better Manage Inflammatory Bowel Disease
University of Maryland School of Medicine

University of Maryland School of Medicine (UMSOM) researchers opened recruitment this month to assess whether a novel remote therapeutic monitoring system can help people with inflammatory bowel disease (IBD) adhere to their medication regimen, and ultimately improve their symptoms and prevent dangerous flare-ups.

Newswise: Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Released: 19-Oct-2022 11:05 AM EDT
Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Rutgers Cancer Institute

Approximately 500 healthy volunteers with no history of cancer are being sought to contribute blood cells that may be used in the development of cancer clinical trials.

Newswise: Landmark Clinical Study Finds Aspirin as Effective as Commonly Used Blood Thinner to Prevent Life-Threatening Blood Clots and Death After Fracture Surgery
Released: 13-Oct-2022 4:30 PM EDT
Landmark Clinical Study Finds Aspirin as Effective as Commonly Used Blood Thinner to Prevent Life-Threatening Blood Clots and Death After Fracture Surgery
University of Maryland School of Medicine

Patients who have surgery to repair bone fractures typically receive a type of injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots, but a new clinical trial found that over-the-counter aspirin is just as effective.

Released: 12-Oct-2022 3:50 PM EDT
Rutgers Seeks Participants for Monkeypox Treatment Study
Rutgers University-New Brunswick

Rutgers New Jersey Medical School is one of nearly 80 sites in the United States that will enroll participants in a new study to evaluate whether tecovirimat is effective in treating human monkeypox.

Released: 12-Oct-2022 3:30 PM EDT
Medicinal cannabis study into easing symptoms of children in palliative care
Murdoch Childrens Research Institute

A Murdoch Children’s Research Institute pilot study will explore the use of medicinal cannabis to reduce symptoms in children and adolescents who are undergoing palliative care for non-cancerous conditions.

Released: 12-Oct-2022 1:05 PM EDT
Bionic Pancreas Improves Type 1 Diabetes Management in Kids and Adults
Ann and Robert H. Lurie Children's Hospital of Chicago

A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found.



close
2.21517